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Córdoba, Argentina, 2 Consejo Nacional de Investigaciones Cientı́ficas y Técnicas (CONICET), Buenos
Aires, Argentina, 3 Instituto de Medicina Traslacional e Ingenierı́a Biomédica (IMTIB)—CONICET—Instituto
Universitario del Hospital Italiano (IUHI)—Hospital Italiano (HIBA), Buenos Aires, Argentina, 4 Sección de
Hepatologı́a, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5 Departamento de Investigación,
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6 Hospital Córdoba, Córdoba, Argentina,
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Little is known about hepatitis E virus (HEV) infection in patients with cirrhosis. The aim of
the present study was to describe the frequency of HEV infection and associated risk factors
in patients with cirrhosis from Argentina.
Materials and methods
We evaluated HEV seroprevalence (IgG anti-HEV) and acute infections (IgM and RNA) in
patients with cirrhosis (n = 140) vs. healthy controls (n = 300). Additionally, we compared
the same outcomes in individuals with alcohol-related cirrhosis (n = 43) vs. patients with
alcohol use disorder (without cirrhosis, n = 72).
Results
The overall HEV seroprevalence in the cohort of subjects with cirrhosis was 25% (35/140),
compared to 4% in the healthy control group [12/300; OR = 8; (95% CI = 4–15.99); p<0.05].
HEV seropositivity was significantly higher in alcohol-related cirrhosis compared to other
causes of cirrhosis [39.5% vs. 12.4%; OR = 4.71; (95% CI = 1.9–11.6); p<0.05] and to
healthy controls [OR = 15.7; (95% CI = 6.8–36.4); p = 0.0001]. The HEV seroprevalence in
alcoholic-related cirrhosis vs. with alcohol use disorder was 39.5% vs. 12.5% [OR = 4.58;
(95% CI = 1.81–11.58); p<0.001].
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Conclusion
We found a high seroprevalence of HEV in patients with cirrhosis and in individuals with
alcohol use disorder. The simultaneous presence of both factors (cirrhosis + alcohol)
showed more association to HEV infection. Larger studies with prospective follow up are
needed to further clarify this interaction.
Introduction
Hepatitis E virus (HEV) (specie Orthohepevirus A, genus Ortohepevirus, family Hepeviridae) is
a non-enveloped virus with a positive sense single stranded RNA genome. It is one of the lead-
ing causes of acute viral hepatitis of enteric transmission worldwide, resulting in a spectrum of
clinical manifestations from self-limiting to fulminant [1,2]. Eight genotypes have been
described, from which 5 can infect humans (1–4 and 7); with 3 of them (3, 4 and 7) considered
zoonotic [2,3].
Multiple studies from a variety of regions around the world, have reported that individuals
with immunosuppression and/or chronic liver disease have higher HEV seroprevalence rates
and a higher risk to develop chronic hepatitis compared to the general population [4–8].
Chronic HEV cases have mostly been observed in these populations when the infecting geno-
type is 3 (HEV-3) [9,10].
An association between HEV infection and progression to cirrhosis in immunocompetent
individuals has also been described [11–14]. However, the underlying mechanisms of this
interrelation are not yet clear. Up to our knowledge, there are only 4 previous studies that
reported high HEV seroprevalence rates in patients with cirrhosis worldwide [15–18].
In South America, sporadic acute HEV cases have been informed and many studies have
documented detection of HEV-3 RNA in a variety of sources, such as animal reservoirs (pigs
and wild boars) and environmental matrices (surface waters and sewage) [3]. Its circulation
has also been reported through serological surveys in many populations (general population,
blood donors, HIV+ individuals, pediatric populations, dialyzed patients, solid organ trans-
plant recipients, etc.) [3]. However, in this region and particularly in Argentina, no study has
yet addressed the association of HEV infection to certain hepatic pathologies, such as
cirrhosis.
In this context, the aim of the present study was to estimate the HEV seroprevalence in
patients with cirrhosis and to evaluate associated risk factors.
Materials and methods
Study design
We performed a cross-sectional study during the years 2017 and 2018 in 1 medical centre
from the city of Buenos Aires (private centre with attending patients on middle and high
incomes) and 2 medical centres from Córdoba (1 private centre, with attending patients on
middle and high incomes, and 1 public centre, with attending individuals on low incomes), all
of them located in the central region of Argentina.
We evaluated HEV seroprevalence (presence of IgG anti-HEV) in patients with cirrhosis
vs. healthy controls. Additionally, we compared values obtained in individuals with alcohol-
related cirrhosis vs. patients with alcohol use disorder (AUD, without cirrhosis, as defined by
[19]).
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With the aim of detecting acute infections, we investigated the presence of IgM anti-HEV
and RNA-HEV.
Samples
a) Cases: patients with cirrhosis (n = 140): analysed for IgG and IgM anti-HEV, as well as
HEV-RNA detection. The diagnosis of cirrhosis was based on liver biopsy or composite of
clinical signs and findings provided by laboratory tests, endoscopy, abdominal Doppler ultra-
sound and radiologic imaging studies. Patients were categorized according to the cause of cir-
rhosis: viral hepatitis n = 23, alcoholic-related cirrhosis n = 43, primary biliary cholangitis
n = 9, non-alcoholic steato-hepatitis (NASH) n = 24 and cirrhosis due to other causes n = 26
(autoimmune hepatitis, cryptogenic hepatitis, secondary biliary cirrhosis).
In 59 patients, biochemical parameters of liver inflammation and function (ALT, AST and
bilirubin levels) were available.
b) Controls: healthy control group of the general population (n = 300): individuals who
attended health-care centres from Córdoba city for a routine control, which were selected
from the serum bank of the Instituto de Virologı́a “Dr. J. M. Vanella”, and retrospectively ana-
lysed as a control group, for IgG anti-HEV detection.
c) Patients with AUD without cirrhosis (n = 72): These patients had fatty liver or liver with-
out alterations (determined by abdominal Doppler ultrasound) and were analysed for IgG and
IgM anti-HEV.
Serological tests
IgG and IgM anti-HEV antibodies were tested by third generation ELISA assays, using com-
mercial kits (Diapro, Italy), following the manufacturer’s instructions and as described before
[3].
In brief, ELISA microplates were coated with HEV-specific, synthetic, conserved and
immunodominant antigens, derived from the open reading frames 2 and 3 (ORF-2 and ORF-
3) of HEV genome of genotypes 1–4. Test results were used to calculate the ratio of the sample
(S) and the cut-off (CO) (S/CO). Samples with S/CO ratio bellow 0.9 were considered negative,
between 0.9–1.1 as equivocal results, and above 1.1 as positive results.
Molecular analyses
IgG and/or IgM anti-HEV positive samples were subjected to HEV molecular detection. For
viral nucleic acids extraction, the QIAamp Viral RNA Kit (Qiagen GmbH, Germany) was
used, following manufacturer’s instructions. To obtain cDNA, retrotranscription (RT) was
carried out using random hexamer primers and the enzyme Reverse Transcriptase (ImPromII
-Reverse Transcriptase- Promega). Genomic detection of HEV was performed with a nested-
PCR protocol, amplifying a 348 bp fragment of the ORF-2 region for HEV 1–4 genotypes, pre-
viously described by [20], using the enzyme GoTaq (Promega) [20]. PCR products were ana-
lyzed by gel electrophoresis using TBE buffer and a 2% agarose gel containing GelRed
(Biotium, Inc), following the manufacturer’s instructions, and visualized under UV light. The
lower limit of detection for this PCR was 31.6 PID (pig infectious dose).
Statistical analyses
Categorical variables are expressed as numbers and percentages. Continuous variables are
expressed as median and range. To assess the association between individual variables and IgG
anti-HEV seropositivity we used an independent t or χ2 test. The strength of association was
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estimated by means of Odds ratios (OR) and 95% confidence intervals (CIs). Statistical signifi-
cance was defined at p<0.05. The statistical package Stata 13.0 was used.
The socioeconomic level (low-income and middle/high-income populations) was stratified
following a classification based on the economic, social and educational level of each person,
according to [21].
Ethics statement
This study was approved by the Ethics Committee of the Health Ministry of the Province of
Córdoba (CIEIS Hospital Privado Universitario de Córdoba, protocol Nº HP-4-231) and the
Ethics Committee of the Hospital Italiano from Buenos Aires (protocol Nº E/127), Argentina.
A written informed consent was obtained for each individual enrolled.
Results
A total of 512 individuals were evaluated for the presence of HEV. The male-to-female ratio
for patients with cirrhosis (n = 140) was 1.8/1, with a mean age of 61 years (23–88 years). The
male-to-female ratio for healthy individuals (n = 300) was 0.3/1, with a median age of 35 years
(20–78 years). The male-to-female ratio and the median age for patients with AUD (n = 72)
was 8/1 and 51 years (27–67 years), respectively.
The IgG anti-HEV seroprevalence in patients with cirrhosis was significantly higher than in
healthy controls (25% vs. 4%, OR = 8, 95% CI: 4–15.99, p<0.001) (Fig 1). Since the median age
of both groups were different, and taking into account that seroprevalence could increase with
age, we further analysed a subgroup of 93 healthy controls with a mean age of 55 years (46–78
years). The HEV seroprevalence obtained in this subgroup was 7.5%, maintaining the signifi-
cant difference with the group of patients with cirrhosis. Added to this, as the male-to-female
ratio was also quite different in patients and general population, we randomly selected a sub-
group of 118 healthy controls with the same male-to-female rate (1.8/1), finding no significant
difference between both groups (25% patients with cirrhosis vs. 4.2% healthy controls).
When stratifying samples according to geographical origin, HEV seroprevalence in individ-
uals with cirrhosis were 18.5% in Cordoba and 33.9% in Buenos Aires, both significantly
higher than the rates reported for general populations in those areas [4% vs. 18.5%; p<0.001
for Córdoba, and 9.5% (previously reported by [22]) vs. 33.9%; p<0.001 for Buenos Aires].
Fig 1. Associated risk factors with HEV seropositivity.
https://doi.org/10.1371/journal.pone.0224404.g001
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No significant differences were found in the HEV seroprevalences when analysing the sam-
ples according to the socioeconomic status.
Of the 35 IgG anti-HEV positive samples in patients with cirrhosis, 16 were reactive for
IgM anti-HEV (45.7%). Three of the 140 samples (2.1%) resulted positive for HEV-RNA
amplification, although the genotype could not be determined. There were no associations
between biochemical parameters and the HEV serological and molecular status.
The seroprevalences of IgG anti-HEV according to the causes of cirrhosis are shown in
Table 1. Overall, HEV seropositivity was significantly higher in alcoholic-related cirrhosis
when compared to the general population (healthy control group) [OR = 15.7; (95% CI = 6.8–
36.4); p<0.001 (Fig 1)] and to other causes of cirrhosis [39.5% vs. 12.4%; OR = 4.71; (95%
CI = 1.9–11.6); p<0.05] (Table 1).
Due to this unexpected association between alcoholic-related cirrhosis and HEV, we later
attempted to determine if alcohol consumption could itself be considered a risk factor for
HEV infection. Nine samples out of 72 AUD without cirrhosis (12.5%) yielded a positive result
for anti-HEV IgG. This percentage was statistically higher than the obtained in the healthy
control group, suggesting a positive association between alcohol consumption and HEV sero-
positivity [12.5% vs. 4%; OR = 3.43; (95% CI = 1.39–8.49, p = 0.005) (Fig 1)]. IgM anti-HEV
was detected in only 1 out of the 9 IgG anti-HEV (+) samples analysed (11%).
RNA-HEV could not be tested in these samples likely due to storing conditions being sub-
optimal to carry out advanced molecular detection.
When comparing the HEV seroprevalence in individuals with alcoholic-related cirrhosis
and AUD we found a statistically significant difference (39.5% vs. 12.5%; p = 0.0008), being
more likely to be HEV seropositive in patients with alcoholic-related cirrhosis [OR = 4.58;
(95% CI = 1.81–11.58)].
Discussion
An association between HEV infection and liver cirrhosis has been reported in several studies;
yet there is a lack of clarity of related risk factors and prognostic significance. It has been
reported that HEV infection could negatively impact the prognosis of patients with chronic
liver diseases [23,24]. However, in Latin America there is only one recent report from Brazil
about HEV infection in individuals with chronic liver disease [17], and no data documented in
Argentina.
In our study, we found that seropositivity for IgG anti-HEV in individuals with cirrhosis
was 7 times higher than that of healthy controls. It is known that HEV seroprevalence varies
Table 1. IgG anti-HEV serostatus in patients with cirrhosis according to the causes of cirrhosis.
Positive Negative Totala
n % n % n %
Alcoholic-related cirrhosisb 17 39.5% 26 60.5% 43 34.7%
Viral hepatitis 3 13.0% 20 87.0% 23 18.6%
NASH 2 8.3% 22 91.7% 24 19.4%
Primariy biliary cholangitis 2 22.2% 7 77.8% 9 7.3%
Other causes c 3 11.5% 23 88.5% 26 21.0%
NASH: non-alcoholic steato-hepatitis.
aAvailable data for 125 patients.
bp-value<0.05; OR = 4.71 (95% IC = 1.9–11.6), when comparing with all the other causes of cirrhosis.
cAutoimmune, cryptogenic and secondary biliary cirrhosis.
https://doi.org/10.1371/journal.pone.0224404.t001
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according to the geographical region (even within a country) and the age of the individuals
analyzed. This is the case of Argentina, where slightly variations in seroprevalence values of
general population have been documented among different studied regions [3] and different
age groups (higher seroprevalences in individuals older than 46 years) [25]. Our samples origi-
nated from two different regions within Argentina. When samples were analyzed stratified
according to their region of origin, we still found significant differences among individuals
with cirrhosis and those of general population in each region. The same was observed when
we compared individuals with cirrhosis and a subgroup of healthy controls with similar ages
and with the same male-to-female ratio, indicating that, in this setting, the high anti-HEV IgG
positivity rate is associated with parameters other than age or sex, probably associated with the
presence of cirrhosis.
Previous studies have reported higher HEV seroprevalence rates in patients with cirrhosis,
such as in Spain (17.5%), China (6.5%), Turkey (25.7%) and recently in Brazil (13.2%), when
compared to those obtained in healthy individuals and patients with chronic hepatitis (without
cirrhosis) from the four regions [15–18]. Interestingly, a study from Spain in HIV infected
patients, found that liver cirrhosis was the only risk factor related to the presence of antibodies
against HEV [26]. In Nepal, a recent research has also documented an association of HEV
seropositivity with an advanced stage of liver fibrosis [27].
It is not totally clear why cirrhosis would predispose to HEV seropositivity. Several studies
have reported that cirrhosis-associated immune dysfunction can lead to alterations in innate
and acquired immunity, both at an intrahepatic and systemic level. This could, in theory,
explain why patients with cirrhosis may be prone to contract HEV infection [28,29]. On the
other hand, the significantly higher seroprevalence of IgG anti-HEV in patients with cirrhosis
compared to the seroprevalence of those with chronic hepatitis (without cirrhosis) found in
the studies from Spain and China [15,16], could be an indication that HEV infection contrib-
utes to the progression of chronic liver disease to cirrhosis.
Interestingly, we found an unexpected high seroprevalence of HEV specifically in patients
with alcoholic-related cirrhosis. This group of patients expressed an increased risk of HEV
infection, 14 times higher than the control group, and 3 times higher than individuals with
other causes of cirrhosis (and with similar ages). To our knowledge, only one previous study
from China has reported a significant association between the seroprevalence of HEV infec-
tion and alcoholic-related cirrhosis, in which a correlation between HEV infection, hepatitis B
and autoimmune hepatitis was also found [16].
Previous studies have proposed alcohol consumption to be considered an important risk
factor for HEV, as it contributes to the clinical expression of the infection and the severity of
hepatitis [30]. Moreover, a study that reported a HEV-3 outbreak on a cruise ship, identified
alcohol consumption as a key risk factor, suggesting that excess alcohol consumption could
compromise hepatic function and predispose to symptomatic hepatitis E infection [31]. Inter-
estingly, a recent report shows that binge alcohol consumption can induce bacterial transloca-
tion into the blood [32]. As transmission of HEV is thought to be fecal-oral via the gut system,
it is not unreasonable to speculate that upon alcohol drinking there could also be a component
of viral, in addition to bacterial, translocation allowing for the exposure to HEV.
In addition, it is known that excessive alcohol consumption can induce subclinical liver dis-
ease (steatosis and/or fibrosis), which increases the susceptibility of the organ to develop viral
infections [30,31,33]. This could lead to more frequent HEV infections (and a consequent
increased seroprevalence), as well as a greater likelihood of symptomatic infections (as
reported by [30]).
Our study found a high seroprevalence of IgM anti-HEV in individuals with alcoholic-
related cirrhosis, suggesting recent infections in the studied population, although there were
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not clinical signs of acute infection and biochemical parameters were within reference values.
Therefore, these results should be interpreted with caution.
Our study has several limitations, including: a) the impossibility of genotyping the RNA
amplified, which was probably due to a low viral load, b) the relatively low number of samples
analyzed, together with the low number of variables analyzed, which did not allow multivariate
analyses discarding possible confounders that could explain our findings more accurately, c)
the lack of sequential testing which would allow to determine whether alcoholic-related cirrho-
sis is a predisposing factor for HEV infection or if HEV infection contributes to progression of
liver fibrosis to cirrhosis.
Larger studies focused on a higher number of individuals with alcoholic-related cirrhosis
with prospective follow up are needed to further clarify this interaction. Moreover, evaluation
of the cellular systemic immune response and liver local immune response with sequential
monitoring of HEV-RNA in individuals with cirrhosis and liver-related cirrhosis would help
to clarify the association and identify potential prevention points.
Author Contributions
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Validation: Julieta Trinks, Sebastián Marciano, Fabián Zárate, Domingo C. Balderramo, Mari-
bel G. Martı́nez Wassaf, Leila Haddad, Adrián Gadano, José D. Debes, Marı́a B. Pisano,
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Balderramo, Maribel G. Martı́nez Wassaf, Leila Haddad, Adrián Gadano, José D. Debes,
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